Yuko Mishima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuko Mishima has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Amir L. Butt
Department of Anesthesiology University of Oklahoma Health Campus Oklahoma City Oklahoma USA
1 shared publication - Jerrold H. Levy
Department of Anesthesiology, Critical Care, and Surgery, Duke University School of Medicine, Durham, NC 27710, USA
1 shared publication - Kenichi A. Tanaka
Department of Anesthesiology, University of Oklahoma Health, Oklahoma City
1 shared publication - Kenneth E. Stewart
University of Oklahoma Health, Oklahoma City, Oklahoma
1 shared publication - Kofi B. Vandyck
Department of Anesthesiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
1 shared publication - Masahito Ueda
Nihon University
1 shared publication
Latest Publications
- 27 January 2026
- Published by Wiley in Transfusion Medicine
- Vol. 36 (3) , 307-308
Are we missing the true impact of ferritin‐guided donor management?
- 27 January 2026
- Published by Wiley in Transfusion Medicine
- Vol. 36 (3) , 307-308
Are we missing the true impact of ferritin‐guided donor management?
- 8 April 2024
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 132 (6) , 1204-1210
Antithrombin supplementation attenuates heparin resistance in plasma spiked with Gla-domainless factor Xa S195A in vitro
- 8 April 2024
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 132 (6) , 1204-1210
Antithrombin supplementation attenuates heparin resistance in plasma spiked with Gla-domainless factor Xa S195A in vitro
- Open Access
- 1 March 1994
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 130 (3) , 320-324
Stable and strong expression of basic fibroblast growth factor in naevus cell naevus contrasts with aberrant expression in melanoma
Summary It has been proposed that basic fibroblast growth factor (bFGF) is an autocrine growth factor of melanoma cells, in contrast with normal melanocytes where bFGF acts as a paracrine growth factor. As this notion is mostly based on the different requirements for bFGF in cultures of benign and malignant pigment cells in vitro, we performed an immunohistochemical study to examine bFGF expression in vivo using paraffin sections from naevus cell naevi (NCN) and malignant melanoma (MM). All the NCN (n=7) showed strong and homogeneous expression of bFGF protein, whereas the primary MMs (n=5) showed heterogeneous expression, with a population of negative cells. Metastatic MMs (n=5) also showed heterogeneous expression, and had a greater population of negative cells. These results suggest that bFGF has some, as yet unidentitied, role in the growth of benign NCN, and that overexpression of bFGF is neither a prerequisite for melanoma genesis nor for progression to metastatic MM.
- 1 March 1994
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 130 (3) , 320-324
Open AccessStable and strong expression of basic fibroblast growth factor in naevus cell naevus contrasts with aberrant expression in melanoma
Summary It has been proposed that basic fibroblast growth factor (bFGF) is an autocrine growth factor of melanoma cells, in contrast with normal melanocytes where bFGF acts as a paracrine growth factor. As this notion is mostly based on the different requirements for bFGF in cultures of benign and malignant pigment cells in vitro, we performed an immunohistochemical study to examine bFGF expression in vivo using paraffin sections from naevus cell naevi (NCN) and malignant melanoma (MM). All the NCN (n=7) showed strong and homogeneous expression of bFGF protein, whereas the primary MMs (n=5) showed heterogeneous expression, with a population of negative cells. Metastatic MMs (n=5) also showed heterogeneous expression, and had a greater population of negative cells. These results suggest that bFGF has some, as yet unidentitied, role in the growth of benign NCN, and that overexpression of bFGF is neither a prerequisite for melanoma genesis nor for progression to metastatic MM.